Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Status:
Recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the effects, both good and bad, of the research study
drug Neratinib in combination with Trastuzumab, Pembrolizumab and FOLFOX chemotherapy. This
study will also look at the safety of Neratinib in combination with Trastuzumab,
Pembrolizumab and FOLFOX in HER2 overexpressing Gastroesophageal cancers.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
National Comprehensive Cancer Network Puma Biotechnology, Inc.